A detailed history of Ubs Group Ag transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 404,118 shares of CCCC stock, worth $2.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
404,118
Previous 696,677 41.99%
Holding current value
$2.42 Million
Previous $5.69 Million 67.19%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.05 - $8.1 $1.18 Million - $2.37 Million
-292,559 Reduced 41.99%
404,118 $1.87 Million
Q1 2024

May 13, 2024

BUY
$5.3 - $11.0 $2.22 Million - $4.6 Million
418,302 Added 150.27%
696,677 $5.69 Million
Q4 2023

Feb 09, 2024

SELL
$1.18 - $6.03 $51,016 - $260,701
-43,234 Reduced 13.44%
278,375 $1.57 Million
Q3 2023

Nov 09, 2023

BUY
$1.81 - $3.89 $93,770 - $201,529
51,807 Added 19.2%
321,609 $598,000
Q2 2023

Aug 11, 2023

BUY
$2.75 - $3.77 $294,668 - $403,963
107,152 Added 65.88%
269,802 $741,000
Q1 2023

May 12, 2023

SELL
$3.1 - $9.02 $333,467 - $970,281
-107,570 Reduced 39.81%
162,650 $510,000
Q4 2022

Feb 08, 2023

SELL
$5.42 - $10.24 $253,791 - $479,488
-46,825 Reduced 14.77%
270,220 $1.59 Million
Q3 2022

Nov 10, 2022

SELL
$8.03 - $12.77 $242,032 - $384,900
-30,141 Reduced 8.68%
317,045 $2.78 Million
Q2 2022

Aug 10, 2022

BUY
$5.06 - $26.46 $89,096 - $465,907
17,608 Added 5.34%
347,186 $2.62 Million
Q1 2022

May 16, 2022

SELL
$19.99 - $33.23 $264,267 - $439,300
-13,220 Reduced 3.86%
329,578 $8 Million
Q4 2021

Feb 14, 2022

SELL
$29.39 - $46.86 $2.19 Million - $3.49 Million
-74,555 Reduced 17.86%
342,798 $11 Million
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $573,841 - $806,990
15,980 Added 3.98%
417,353 $18.6 Million
Q2 2021

Aug 13, 2021

BUY
$30.39 - $42.18 $4.22 Million - $5.86 Million
138,935 Added 52.94%
401,373 $15.2 Million
Q1 2021

May 12, 2021

BUY
$31.96 - $46.5 $5.17 Million - $7.52 Million
161,722 Added 160.57%
262,438 $9.71 Million
Q4 2020

Feb 11, 2021

BUY
$22.8 - $37.05 $2.3 Million - $3.73 Million
100,716 New
100,716 $3.34 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $293M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.